Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.

@article{Brewer2006TreatmentOW,
  title={Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.},
  author={George J. Brewer and Fred K. Askari and Matthew T. Lorincz and Martha L Carlson and Michael L. Schilsky and Karen J. Kluin and Peter Hedera and Paolo M. Moretti and John K. Fink and Roberta M Tankanow and Robert B Dick and Julia Sitterly},
  journal={Archives of neurology},
  year={2006},
  volume={63 4},
  pages={521-7}
}
OBJECTIVE To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for the frequency of neurologic worsening, adverse effects, and degree of neurologic recovery. DESIGN A randomized, double-blind, controlled, 2-arm study of 48 patients with the neurologic presentation of Wilson disease. Patients either received 500 mg of trientine hydrochloride 2 times per day or 20 mg of tetrathiomolybdate 3 times per day with meals and 20 mg 3 times… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management

  • GJ Brewer
  • 2001

Similar Papers

Loading similar papers…